Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Monte Rosa Therapeutics (GLUE) EBIAT (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of EBIAT data on record, last reported at -$27.1 million in Q3 2025.

  • For Q3 2025, EBIAT fell 13.5% year-over-year to -$27.1 million; the TTM value through Sep 2025 reached $20.9 million, up 117.51%, while the annual FY2024 figure was -$72.7 million, 46.29% up from the prior year.
  • EBIAT reached -$27.1 million in Q3 2025 per GLUE's latest filing, down from -$12.3 million in the prior quarter.
  • Across five years, EBIAT topped out at $46.9 million in Q1 2025 and bottomed at -$35.2 million in Q2 2023.
  • Average EBIAT over 3 years is -$18.2 million, with a median of -$30.3 million recorded in 2024.
  • The widest YoY moves for EBIAT: up 246.66% in 2025, down 13.5% in 2025.
  • A 3-year view of EBIAT shows it stood at -$33.3 million in 2023, then skyrocketed by 140.3% to $13.4 million in 2024, then tumbled by 302.1% to -$27.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$27.1 million in Q3 2025, -$12.3 million in Q2 2025, and $46.9 million in Q1 2025.